We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma.
- Authors
Santen, Richard J.; Worgul, Thomas J.; Lipton, Allan; Harvey, Harold; Boucher, Alice; Samojlik, Eugeniusz; Wells, Samuel A.; Santen, R J; Worgul, T J; Lipton, A; Harvey, H; Boucher, A; Samojlik, E; Wells, S A
- Abstract
Hormone-dependent breast carcinomas respond to deprivation of biologically active estrogens with objectively quantifiable tumor regression. Aminoglutethimide, a known inhibitor of steroid synthesis, is also a potent blocker of the aromatase enzyme and, thus, of estrogen production. We developed an effective regimen to inhibit estrogen production in postmenopausal women using aminoglutethimide and replacement glucocorticoid. One hundred forty-seven women initially received aminoglutethimide and replacement glucocorticoid as treatment of metastatic breast carcinoma. One hundred twenty-nine women are currently evaluable for assessment of clinical and hormonal responses. Thirty-seven percent of unselected women and 49% of estrogen receptor-positive patients experienced objective tumor regression. Responses occurred predominantly in soft tissue (47%) and bone (35%) and lasted 30 +/- 9.1 months for complete and 14 +/- 1.5 months for partial regressions. Plasma and urinary estrogen levels fell equally in responder versus nonresponder groups whereas androgen levels declined less in patients with progressive disease.
- Subjects
BREAST diseases; SPONTANEOUS cancer regression; AMINOGLYCOSIDES; THERAPEUTIC use of glucocorticoids; THERAPEUTICS
- Publication
Annals of Internal Medicine, 1982, Vol 96, Issue 1, p94
- ISSN
0003-4819
- Publication type
journal article
- DOI
10.7326/0003-4819-96-1-94